a public good project by the
Synthesis
Company
of California

© 2026

Hidehisa Saeki | doi.page

0 works0 citations0 h-index

Hidehisa Saeki

Nippon Medical School(JP)

Publications by Year

Research Areas

Dermatology and Skin Diseases, Asthma and respiratory diseases, Allergic Rhinitis and Sensitization, Psoriasis: Treatment and Pathogenesis, Urticaria and Related Conditions

Most-Cited Works

→ Cutting Edge: Secondary Lymphoid-Tissue Chemokine (SLC) and CC Chemokine Receptor 7 (CCR7) Participate in the Emigration Pathway of Mature Dendritic Cells from the Skin to Regional Lymph Nodes(1999)622 cited
→ Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity(2001)566 cited
→ Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*(2020)563 cited
→ Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population(2012)349 cited
→ Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases(2006)270 cited
→ Guidelines for management of atopic dermatitis(2009)265 cited

→ Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study(2020)230 cited

→ Japanese guidelines for atopic dermatitis 2020(2020)193 cited

→ Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J)(2016)190 cited

→ Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris(2002)189 cited